查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654649

全球鼻腔給藥技術市場 - 2025 至 2033 年

Global Nasal Drug Delivery Technology Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球鼻腔給藥技術市場規模達到 816.9 億美元，預計到 2033 年將達到 1,369.7 億美元，2025-2033 年預測期內的複合年成長率為 6.7%。

鼻腔給藥技術是指透過鼻腔給藥來達到治療效果的技術。這種藥物輸送途徑因其方便、有效，且能夠繞過胃腸系統和肝臟首過代謝，從而減少副作用並提高藥物的生物利用度，而得到越來越多的應用。鼻腔給藥技術是利用鼻腔噴霧劑、粉劑和氣霧劑將藥物透過鼻黏膜直接輸送到血液中。這種方法特別有利於遞送胜肽、蛋白質、疫苗和其他藥物，這些藥物在胃腸道中分解或吸收不良而口服時可能無效。

由於鼻腔給藥技術具有非侵入性、便利性和患者依從性提高的特點，市場對鼻腔給藥技術的需求正在迅速成長。這些技術的採用率受到多種因素的推動，其中包括在慢性病管理中的應用日益增多，例如，根據美國疾病管制與預防中心的數據，估計美國有 1.29 億人患有至少 1 種主要慢性病。根據世界衛生組織的數據，到2030年，全球每6人中就有1人年齡在60歲或以上，這一老齡化人口需要更簡單、更可接受的治療方案，這增加了對鼻腔給藥技術的需求。

市場動態：

促進因素與約束因素

奈米技術不斷進步

奈米技術的不斷進步極大地推動了鼻腔藥物輸送技術市場的成長，並有望在預測期內透過開發更高效、更有針對性的藥物輸送系統來推動市場發展。這些創新提高了經鼻給藥的藥物的穩定性、生物利用度和患者依從性，增強了藥物的有效性。

例如，2024 年 10 月，來自莫哈里奈米科學技術研究所 (INST) 的研究人員開發了一種新型藥物傳輸系統，用於治療中樞神經系統結核病 (CNS-TB)。這種尖端方法透過鼻腔途徑將抗結核病 (TB) 藥物直接輸送到大腦，克服了血腦屏障 (BBB) 帶來的限制。

奈米技術涉及使用奈米粒子，可以將藥物直接穿過鼻粘膜進入血液。這些奈米粒子可以保護藥物免於分解，並增強其穩定性和生物利用度。這對於胜肽和蛋白質特別有益，因為它們口服時通常不穩定。

此外，2024 年 11 月，Virpax Pharmaceuticals, Inc. 與美國國家推動轉化科學中心 (NCATS) 的合作研發協議獲得延期。此次合作是為了繼續開發 Virpax 的候選產品 NES100（一種鼻內肽），用於治療急性和慢性非癌症疼痛。 NES100 是一種基於奈米技術輸送方法的腦啡肽藥物產品。腦啡肽是一種天然存在的（內源性）胜肽，不易以其原始形式給藥。

不良反應和安全問題

不良反應和安全問題是阻礙鼻腔給藥技術市場成長的重大挑戰。這些問題可能會影響患者和醫療保健提供者對鼻腔給藥系統的接受度和採用。鼻腔給藥有時會引起鼻黏膜的刺激或過敏反應。這會導致不適，且患者不願意使用鼻腔噴劑或粉末。乾燥、打噴嚏或鼻塞等局部副作用是鼻腔給藥技術的常見問題。

例如，使用含有皮質類固醇的鼻腔噴劑來治療過敏，會引起局部刺激，導致流鼻血或鼻腔灼熱感。這些不良影響可能會使患者不願意繼續治療。

雖然鼻腔給藥最大限度地減少了首過代謝，但仍存在全身性吸收的風險，特別是對於旨在局部作用的藥物。這可能會導致意想不到的全身性副作用，從而限制某些藥物在鼻腔製劑中的使用。例如，對於像鼻減充血劑這樣用於局部作用的藥物，仍可能會發生全身吸收，可能導致心率加快和血壓增加等心血管影響。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 以劑型分類
  • 按應用程式截取的程式碼片段
  • 按配銷通路分類
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 奈米技術不斷進步
      • 技術合作與合併不斷增多
    • 限制
      • 不良反應和安全問題
    • 機會
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • 新興創業公司和關鍵創新者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：鼻腔給藥技術市場（依劑型分類）

  • 噴霧劑
  • 掉落
  • 粉末
  • 啫咖哩

第 6 章：鼻腔給藥技術市場（依應用）

  • 呼吸系統疾病
    • 氣喘
    • 慢性阻塞性肺病 (COPD)
    • 過敏性鼻炎
    • 鼻竇炎
    • 其他
  • 中樞神經系統疾病
    • 偏頭痛
    • 帕金森氏症
    • 阿茲海默症
  • 疼痛管理
  • 其他

第 7 章：鼻腔給藥技術市場（依配銷通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 8 章：鼻腔給藥技術市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Pfizer Inc.
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 關鍵進展
    • SWOT 分析
  • Becton, Dickinson and Company
  • AstraZeneca PLC
  • AptarGroup, Inc.
  • MetP Pharma AG
  • GlaxoSmithKline Inc.
  • Hikma Pharmaceuticals PLC
  • Currax Pharmaceuticals LLC.
  • Tonix Medicines, Inc.
  • Johnson & Johnson

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD9094

The global nasal drug delivery technology market reached US$ 81.69 billion in 2024 and is expected to reach US$ 136.97 billion by 2033, growing at a CAGR of 6.7% during the forecast period 2025-2033.

Nasal drug delivery technology refers to the administration of drugs through the nasal cavity to achieve therapeutic effects. This route of drug delivery is increasingly being used for its convenience, efficiency, and ability to bypass the gastrointestinal system and hepatic first-pass metabolism, which can reduce side effects and improve drug bioavailability. Nasal drug delivery technology involves the use of nasal sprays, powders and aerosols to deliver drugs directly into the bloodstream via the nasal mucosa. This method is particularly beneficial for the delivery of peptides, proteins, vaccines and other drugs that may not be effective when administered orally due to degradation in the gastrointestinal tract or poor absorption.

The market demand for nasal drug delivery technology is growing rapidly due to its non-invasive nature, convenience and improved patient compliance. The adoption rate of these technologies is being driven by several factors including increasing applications in chronic disease management, for instance, according to the Centers for Disease Control and Prevention, an estimated 129 million people in the US have at least 1 major chronic disease. According to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over, this aging population requires easier and more acceptable treatment options, which increases the demand for nasal drug delivery technology.

Market Dynamics: Drivers & Restraints

Rising advancements in nanotechnology

The rising advancements in nanotechnology are significantly driving the growth of the nasal drug delivery technology market and are expected to drive the market over the forecast period by enabling the development of more efficient and targeted drug delivery systems. These innovations enhance the effectiveness of drugs delivered through the nasal route by improving their stability, bioavailability and patient compliance.

For instance, in October 2024, researchers from the Institute of Nano Science and Technology (INST), Mohali, developed a novel drug delivery system to treat Central Nervous System Tuberculosis (CNS-TB). This cutting-edge method delivers anti-tuberculosis (TB) drugs directly to the brain through the nasal route, overcoming the limitations posed by the blood-brain barrier (BBB).

Nanotechnology involves the use of nanoparticles that can carry drugs directly across the nasal mucosa into the bloodstream. These nanoparticles can protect drugs from degradation, enhancing their stability and bioavailability. This is particularly beneficial for peptides and proteins, which are typically unstable when administered orally.

Additionally, in November 2024, Virpax Pharmaceuticals, Inc. was granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS). This collaboration is for the continued development of Virpax's product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form.

Adverse effects and safety concerns

Adverse effects and safety concerns are significant challenges hampering the growth of the nasal drug delivery technology market. These issues can impact the acceptability and adoption of nasal drug delivery systems by both patients and healthcare providers. Nasal drug delivery can sometimes cause irritation or allergic reactions in the nasal mucosa. This can lead to discomfort and patient reluctance to use nasal sprays or powders. Localized side effects such as dryness, sneezing or nasal congestion are common issues with nasal drug delivery technologies.

For instance, the use of corticosteroids in nasal sprays for managing allergies can result in local irritation, leading to nosebleeds or a burning sensation in the nasal passages. Such adverse effects can discourage patients from continuing treatment.

Although nasal delivery minimizes first-pass metabolism, there is still a risk of systemic absorption, especially for drugs that are intended to act locally. This can lead to unintended systemic side effects, which can limit the use of certain drugs in nasal formulations. For instance, for drugs intended for local action like nasal decongestants, systemic absorption may still occur, potentially leading to cardiovascular effects such as increased heart rate and blood pressure.

Segment Analysis

The global nasal drug delivery technology market is segmented based on dosage form, application, distribution channel and region.

Application:

The respiratory diseases segment is expected to dominate the nasal drug delivery technology market share

Nasal drug delivery systems are highly effective for treating allergic rhinitis and asthma, which are common respiratory conditions. These conditions require frequent medication administration, and nasal sprays are particularly suitable due to their quick onset of action and localized effects. Nasal corticosteroids are the primary drugs used in this segment, offering targeted anti-inflammatory action directly to the nasal mucosa, which minimizes systemic side effects.

For instance, in January 2023, Airsupra (albuterol/budesonide), formerly known as PT027, which is developed by AstraZeneca and Avillion, was approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.

The nasal route allows for quick absorption of drugs into the bloodstream, which is particularly advantageous for managing acute symptoms of respiratory diseases like asthma attacks. Drugs administered via the nasal route can bypass the gastrointestinal system and avoid the first-pass metabolism in the liver, ensuring higher bioavailability and faster therapeutic effects.

Geographical Analysis

North America is expected to hold a significant position in the nasal drug delivery technology market share

Major pharmaceutical companies and research institutions in North America especially in the United States, are investing heavily in the development and commercialization of nasal drug delivery systems. Companies like Pfizer, Johnson & Johnson, Amneal Pharmaceuticals, Inc. and other emerging players have been at the forefront, with nasal drug formulations being a key component of their respiratory disease management strategies by FDA approvals.

For instance, in April 2024, Amneal Pharmaceuticals, Inc. announced the availability of Over the Counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (FDA). Amneal's Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC NARCAN HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.

Additionally, in September 2024, Renaissance Lakewood, LLC manufactured neffy. The FDA approved and became the first and only needle-free, intranasal spray treatment for Type I allergic reactions, including anaphylaxis in adults and children. neffy is an easy-to-carry and easy-to-use epinephrine medication alternative to needle-based treatments for potentially life-threatening allergic reactions. neffy marks the first regulatory approval worldwide for epinephrine delivered as an intra-nasal spray.

Asia-Pacific is growing at the fastest pace in the nasal drug delivery technology market

The healthcare infrastructure in the Asia-Pacific region has been rapidly improving. Countries like India, China, Japan and South Korea are investing heavily in healthcare, including the establishment of new medical facilities and research centers. For instance, according to the India Brand Equity Foundation (IBEF), under the PLI scheme for Medical Devices, till now, a total of 26 projects have been approved, with a committed investment of US$ 147 million. These rising investments and developments have facilitated the adoption of advanced drug delivery technologies, including nasal drug delivery systems.

In March 2024, Aurobindo Pharma added 1.28% to Rs 1,002.05 after the drug maker received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray. The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray of Organon LLC. The product will be launched in Q1 FY25. Mometasone Furoate Monohydrate Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.

The APAC region is witnessing rapid adoption of new drug delivery technologies, including nanotechnology and controlled release systems for nasal drug delivery. Companies in the region along with strategic partnerships and mergers, innovating and distributing nasal formulations that cater to regional needs. For instance, Altamira Therapeutics Ltd. announced that its associate company Altamira Medica Ltd. agreed with its partner Nuance Pharma, Shanghai, China to extend the territory covered by their exclusive license and distribution agreement for Bentrio nasal spray by several countries across South East and East Asia.

Competitive Landscape

The major global players in the nasal drug delivery technology market include Pfizer Inc., Becton, Dickinson and Company, AstraZeneca PLC, AptarGroup, Inc., MetP Pharma AG, GlaxoSmithKline Inc., Hikma Pharmaceuticals PLC, Currax Pharmaceuticals LLC., Tonix Medicines, Inc., Johnson & Johnson and among others.

Key Developments

  • In October 2024, Aero Pump and Resyca announced their collaboration in the launch of the innovative Ultra Soft Nasal Pump Spray. Available for licensing immediately, this co-developed system represents a new frontier in nasal drug delivery, offering enhanced delivery efficiency, precision and comfort for users.
  • In April 2024, Aptar Pharma launched APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations. APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors, thereby minimizing separation efforts in recycling streams and supporting a higher quality of recyclates.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nasal drug delivery technology market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Dosage Form
  • 2.4. Snippet by Application
  • 2.5. Snippet by Distribution Channel
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Nanotechnology
      • 3.1.1.2. Rising Technological Collaborations and Mergers
    • 3.1.2. Restraints
      • 3.1.2.1. Adverse Effects and Safety Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Nasal Drug Delivery Technology Market, By Dosage Form

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 5.1.2. Market Attractiveness Index, By Dosage Form
  • 5.2. Sprays*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Drops
  • 5.4. Powders
  • 5.5. Gels

6. Nasal Drug Delivery Technology Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Respiratory Diseases*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Asthma
    • 6.2.4. Chronic Obstructive Pulmonary Disease (COPD)
    • 6.2.5. Allergic Rhinitis
    • 6.2.6. Sinusitis
    • 6.2.7. Others
  • 6.3. CNS Disorders
    • 6.3.1. Migraine
    • 6.3.2. Parkinson's Disease
    • 6.3.3. Alzheimer's Disease
  • 6.4. Pain Management
  • 6.5. Others

7. Nasal Drug Delivery Technology Market, By Distribution Channel

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 7.1.2. Market Attractiveness Index, By Distribution Channel
  • 7.2. Hospital Pharmacies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Nasal Drug Delivery Technology Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Pfizer Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Becton, Dickinson and Company
  • 10.3. AstraZeneca PLC
  • 10.4. AptarGroup, Inc.
  • 10.5. MetP Pharma AG
  • 10.6. GlaxoSmithKline Inc.
  • 10.7. Hikma Pharmaceuticals PLC
  • 10.8. Currax Pharmaceuticals LLC.
  • 10.9. Tonix Medicines, Inc.
  • 10.10. Johnson & Johnson

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us